Literature DB >> 25868421

Perfluorooctanoic acid (PFOA) affects distinct molecular signalling pathways in human primary hepatocytes.

Thorsten Buhrke1, Eileen Krüger2, Sophie Pevny2, Manuela Rößler2, Katja Bitter2, Alfonso Lampen2.   

Abstract

Perfluorooctanoic acid (PFOA) was shown to damage the liver of rodents and to impair embryonic development. At the molecular level, the hepatotoxic effects were attributed to the PFOA-mediated activation of peroxisome proliferator-activated receptor alpha (PPARα). In general, PPARα-dependent effects are less pronounced in humans than in rodents, and the hazard potential of PFOA for humans is controversially discussed. To analyse the effects of PFOA in human hepatocytes, a microarray analysis was conducted to screen for PFOA-mediated alterations in the transcriptome of human primary hepatocytes. A subsequent network analysis revealed that PFOA had an impact on several signalling pathways in addition to the well-known activation of PPARα. The microarray data confirmed earlier findings that PFOA: (i) affects the estrogen receptor ERα, (ii) activates the peroxisome proliferator-activated receptor gamma (PPARγ), and (iii) inhibits the function of the hepatocyte nuclear factor 4α (HNF4α) which is an essential factor for liver development and embryogenesis. Finally, as a novel finding, PFOA was shown to stimulate gene expression of the proto-oncogenes c-Jun and c-Fos. This was confirmed by using the HepG2 cell line as a model for human hepatocytes. PFOA stimulated cellular proliferation and the metabolic activity of the cells, and upregulated the expression of various cyclins which have a central function in the regulation of cell cycle control. Functional studies, however, indicated that PFOA had no impact on c-Jun and c-Fos phosphorylation and on AP-1-dependent gene transcription, thus demonstrating that PFOA-induced proliferation occurs largely independent of c-Jun and c-Fos.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cell cycle regulation; Hepatocyte; PFOA; Transcriptomics

Mesh:

Substances:

Year:  2015        PMID: 25868421     DOI: 10.1016/j.tox.2015.04.004

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  22 in total

1.  Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014.

Authors:  Franco Scinicariello; Melanie C Buser; Lina Balluz; Kimberly Gehle; H Edward Murray; Henry G Abadin; Roberta Attanasio
Journal:  Chemosphere       Date:  2020-06-20       Impact factor: 7.086

2.  PFOS, PFNA, and PFOA sub-lethal exposure to embryonic zebrafish have different toxicity profiles in terms of morphometrics, behavior and gene expression.

Authors:  Carrie E Jantzen; Kate A Annunziato; Sean M Bugel; Keith R Cooper
Journal:  Aquat Toxicol       Date:  2016-03-31       Impact factor: 4.964

3.  Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults-longitudinal analysis of the diabetes prevention program outcomes study.

Authors:  Pi-I D Lin; Andres Cardenas; Russ Hauser; Diane R Gold; Ken P Kleinman; Marie-France Hivert; Abby F Fleisch; Antonia M Calafat; Thomas F Webster; Edward S Horton; Emily Oken
Journal:  Environ Int       Date:  2019-05-28       Impact factor: 9.621

4.  Perfluorooctanoic acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARα mice fed an American diet.

Authors:  J J Schlezinger; H Puckett; J Oliver; G Nielsen; W Heiger-Bernays; T F Webster
Journal:  Toxicol Appl Pharmacol       Date:  2020-08-19       Impact factor: 4.219

5.  The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction.

Authors:  Kevin M Beggs; Steven R McGreal; Alex McCarthy; Sumedha Gunewardena; Jed N Lampe; Christoper Lau; Udayan Apte
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-03       Impact factor: 4.219

6.  Environmental perfluoroalkyl acid exposures are associated with liver disease characterized by apoptosis and altered serum adipocytokines.

Authors:  John Bassler; Alan Ducatman; Meenal Elliott; Sijin Wen; Banrida Wahlang; John Barnett; Matthew C Cave
Journal:  Environ Pollut       Date:  2019-01-18       Impact factor: 8.071

7.  PPARα-independent transcriptional targets of perfluoroalkyl acids revealed by transcript profiling.

Authors:  Mitchell B Rosen; Kaberi P Das; John Rooney; Barbara Abbott; Christopher Lau; J Christopher Corton
Journal:  Toxicology       Date:  2017-05-27       Impact factor: 4.221

8.  Hepatic carboxylesterases are differentially regulated in PPARα-null mice treated with perfluorooctanoic acid.

Authors:  Xia Wen; Angela A Baker; Curtis D Klaassen; J Christopher Corton; Jason R Richardson; Lauren M Aleksunes
Journal:  Toxicology       Date:  2019-01-24       Impact factor: 4.221

9.  Association between gestational PFAS exposure and Children's adiposity in a diverse population.

Authors:  Michael S Bloom; Sarah Commodore; Pamela L Ferguson; Brian Neelon; John L Pearce; Anna Baumer; Roger B Newman; William Grobman; Alan Tita; James Roberts; Daniel Skupski; Kristy Palomares; Michael Nageotte; Kurunthachalam Kannan; Cuilin Zhang; Ronald Wapner; John E Vena; Kelly J Hunt
Journal:  Environ Res       Date:  2021-07-31       Impact factor: 6.498

10.  Prenatal Exposure to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver Injury in Children.

Authors:  Nikos Stratakis; David V Conti; Ran Jin; Katerina Margetaki; Damaskini Valvi; Alexandros P Siskos; Léa Maitre; Erika Garcia; Nerea Varo; Yinqi Zhao; Theano Roumeliotaki; Marina Vafeiadi; Jose Urquiza; Silvia Fernández-Barrés; Barbara Heude; Xavier Basagana; Maribel Casas; Serena Fossati; Regina Gražulevičienė; Sandra Andrušaitytė; Karan Uppal; Rosemary R C McEachan; Eleni Papadopoulou; Oliver Robinson; Line Småstuen Haug; John Wright; Miriam B Vos; Hector C Keun; Martine Vrijheid; Kiros T Berhane; Rob McConnell; Lida Chatzi
Journal:  Hepatology       Date:  2020-10-19       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.